Abiomed (Abiomed) GF Value : $349.63 (As of May. 11, 2024)

View and export this data going back to 1987. Start your Free Trial

What is Abiomed GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-11), Abiomed's share price is $381.02. Abiomed's GF Value is $349.63. Therefore, Abiomed's Price-to-GF-Value for today is 1.09.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Abiomed is Data Out of Date, Use Caution.

Abiomed (NAS:ABMD) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Abiomed's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	381.02	/	349.63
	=	1.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abiomed GF Value Related Terms

Thank you for viewing the detailed overview of Abiomed's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Abiomed (Abiomed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abiomed Inc (NAS:ABMD) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Cherry Hill Drive, Danvers, MA, USA, 01923

Website

https://www.abiomed.com

Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.

Executives

Matthew T. Plano	officer: VP, GLOBAL OPERATIONS	C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Martin P Sutter	director	2170 BUCKTHORNE PLACE, SUITE 170, THE WOODLAND TX 77380
David M Weber	officer: Chief Operating Officer	2341 ROMANO CIRCLE, PLEASANTON CA 94566
Todd A Trapp	officer: Vice President, CFO	C/O WATTS WATER TECHNOLOGIES, INC., 815 CHESTNUT STREET, NORTH ANDOVER MA 01845
Michael R Minogue	director, officer: President & CEO	22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Paul Thomas	director	ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Paula A Johnson	director	22 CHERRY HILL DRIVE, DANVERS MA 01923
Myron L Rolle	director	1 NASHUA STREET, APARTMENT 1701, BOSTON MA 02114-1625
Dorothy E Puhy	director	DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Andrew J Greenfield	officer: VP Healthcare Solutions	14 HILLSIDE DRIVE, GEORGETOWN MA 01833
Marc A Began	officer: VP & General Counsel	C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Michael G Howley	officer: Vice President	22 CHERRY HILL DRIVE, DANVERS MA 01923
William J Bolt	officer: SVP, DA and QA	C/O ABIOMED INC, 22 CHERRY HILL DRIVE, DANVERS MA 01923
Rose Eric A Md	director	161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Henri A Termeer	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139